
Rafael Holdings (RFL) announced that its subsidiary, Cyclo Therapeutics, has submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration seeking approval of remibetadex for the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| RFL | Rafael Holdings | 0.92 | -0.24 | -20.49% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.92 | -20.49% |

Rafael Holdings (RFL) announced that its subsidiary, Cyclo Therapeutics, has submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration seeking approval of remibetadex for the

An announcement from Rafael Holdings ( ($RFL) ) is now available. Rafael Holdings reported results for the fourth quarter and full fiscal year ended July 31, 2026, highlighting progress across

Rafael Holdings ( ($RFL) ) has issued an update. On September 30, 2026, Rafael Holdings reported topline Phase 3 data from its TransportNPC study of Trappsol Cyclo in 94 Niemann‑Pick

Rafael Holdings (RFL) announced topline efficacy and safety data from its Cyclo Therapeutics subsidiary’s pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in 94 patients diagnosed with Niemann-Pick Disease Type

Rafael Holdings ( ($RFL) ) just unveiled an announcement. On June 10, 2026, Rafael Holdings announced that the last patient completed the final 96-week visit in its pivotal Phase 3

Rafael Holdings (RFL) announced the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease

Rafael Holdings ( ($RFL) ) has issued an announcement. On April 22, 2026, Rafael Holdings said its subsidiary Cyclo Therapeutics signed an exclusive license with MIT for a U.S. patent

Rafael Holdings ( ($RFL) ) just unveiled an announcement. Rafael Holdings, Inc. has issued 1,078,796 warrants, exercisable for 380,253 shares of its Class B common stock, as part of a

Rafael Holdings ( ($RFL) ) has released its Q4 earnings. Here is a breakdown of the information Rafael Holdings presented to its investors. Rafael Holdings, Inc. is a biotechnology company

Rafael Holdings ( ($RFL) ) has shared an update. On October 23, 2025, Rafael Holdings announced the appointment of Alan Grayson to its Board of Directors, following the passing of
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Dec 16, 2026TBA | $50.64M | ― | ― | 0.08 | -1.72 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.